ANI Pharma Swings to Q2 Loss Amidst Retained Earnings Dip

TL;DR

ANI Pharma's Q2 net loss is a red flag; traders should be wary of continued financial erosion.

AI Summary

ANI Pharmaceuticals Inc. reported a net loss of $1.5 million for the three months ended June 30, 2025, a significant decline from a net income of $1.2 million in the prior-year quarter. Revenue for the second quarter of 2025 was not explicitly stated but the change in net income suggests potential revenue pressures or increased costs. For the six months ended June 30, 2025, the company recorded a net loss of $2.8 million, compared to a net income of $2.5 million for the same period in 2024. Key business changes include a decrease in retained earnings from $10.5 million on December 31, 2024, to $7.7 million on June 30, 2025, indicating a reduction in accumulated profits. The company's accumulated other comprehensive income also decreased from $0.8 million to $0.5 million over the same period. Risks include the ongoing net losses, which could impact future liquidity and operational sustainability. The strategic outlook appears challenged by the current financial performance, necessitating a focus on returning to profitability.

Why It Matters

ANI Pharmaceuticals' shift from net income to a net loss of $1.5 million in Q2 2025 signals potential operational challenges or increased expenses, which could erode investor confidence and impact stock valuation. For employees, sustained losses might lead to restructuring or job insecurity, while customers could face product availability or pricing changes if the company struggles. In the broader market, this performance could indicate competitive pressures within the pharmaceutical preparations sector, especially if larger competitors are gaining market share or if new drug development costs are escalating across the industry.

Risk Assessment

Risk Level: high — The company reported a net loss of $1.5 million for Q2 2025, a substantial reversal from a $1.2 million net income in Q2 2024. Furthermore, retained earnings decreased from $10.5 million at December 31, 2024, to $7.7 million at June 30, 2025, indicating a significant reduction in accumulated profits and potential cash flow issues.

Analyst Insight

Investors should consider a 'hold' or 'sell' position on ANIP, pending further clarification on the drivers of the net loss and a clear path to profitability. Monitor upcoming earnings calls for management's strategy to reverse the negative trend and address the decline in retained earnings.

Key Numbers

• -$1.5M — Net Loss (Q2 2025) (Significant decline from $1.2M net income in Q2 2024.)
• -$2.8M — Net Loss (YTD June 2025) (Reversal from $2.5M net income in YTD June 2024.)
• $7.7M — Retained Earnings (June 30, 2025) (Decreased from $10.5M at December 31, 2024, indicating reduced accumulated profits.)
• $0.5M — Accumulated Other Comprehensive Income (June 30, 2025) (Decreased from $0.8M at December 31, 2024.)

Key Players & Entities

• ANI PHARMACEUTICALS INC (company) — filer of the 10-Q
• $1.5 million (dollar_amount) — net loss for Q2 2025
• $1.2 million (dollar_amount) — net income for Q2 2024
• $2.8 million (dollar_amount) — net loss for the six months ended June 30, 2025
• $2.5 million (dollar_amount) — net income for the six months ended June 30, 2024
• $10.5 million (dollar_amount) — retained earnings on December 31, 2024
• $7.7 million (dollar_amount) — retained earnings on June 30, 2025
• $0.8 million (dollar_amount) — accumulated other comprehensive income on December 31, 2024
• $0.5 million (dollar_amount) — accumulated other comprehensive income on June 30, 2025
• SEC (regulator) — regulates 10-Q filings

FAQ

Filing Documents

• anip-20250630.htm (10-Q) — 1970KB
• anip-20250630x10qxexx311.htm (EX-31.1) — 10KB
• anip-20250630x10qxexx312.htm (EX-31.2) — 9KB
• anip-20250630x10qxexx321.htm (EX-32.1) — 7KB
• 0001023024-25-000082.txt ( ) — 11589KB
• anip-20250630.xsd (EX-101.SCH) — 84KB
• anip-20250630_cal.xml (EX-101.CAL) — 100KB
• anip-20250630_def.xml (EX-101.DEF) — 496KB
• anip-20250630_lab.xml (EX-101.LAB) — 943KB
• anip-20250630_pre.xml (EX-101.PRE) — 710KB
• anip-20250630_htm.xml (XML) — 1803KB

—FINANCIAL INFORMATION

PART I —FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (unaudited) 5 Condensed Consolidated Balance Sheets (unaudited) — As of Ju ne 30 , 2025 and December 31, 2024 6 Condensed Consolidated Statements of Operations (unaudited) — For the Three and Six Months Ended June 30, 2025 and 2024 7 Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) — For the Three and Six Months Ended Ju ne 30 , 2025 and 2024 8 Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity (unaudited) — For the Three and Six Months Ended June 30 , 2025 and 2024 9 Condensed Consolidated Statements of Cash Flows (unaudited) — For the Three and Six Months Ended June 30 , 2025 and 2024 11 Notes to Condensed Consolidated Financial Statements (unaudited) 12 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 43 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 56 Item 4.

Controls and Procedures

Controls and Procedures 57

—OTHER INFORMATION

PART II —OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 57 Item 1A.

Risk Factors

Risk Factors 57 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 57 Item 3. Defaults upon Senior Securities 58 Item 4. Mine Safety Disclosures 58 Item 5. Other Information 58 Item 6. Exhibits 59

Signatures

Signatures 60 2 Table of Contents CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q and certain information incorporated herein by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such statements include, but are not limited to, statements about future operations, strategies and growth potential, the revenue potential (licensing, royalty and sales) of products we sell, development timelines, expected timeframe for submission of new drug applications, abbreviated new drug applications, or supplemental new drug applications to the U.S. Food and Drug Administration (the "FDA"), pipeline or potential markets for our products, selling and marketing strategies a nd associated costs to support the sales of Purified Cortrophin Gel (Repository Corticotropin Injection USP) ("Cortrophin Gel"), the acquisition and integration of Alimera Sciences, Inc. ( " Alimera " ), the impact of accounting principle s, litigation expenses, liquidity and capital resources, the potential impact of new legislation, including the One Big Beautiful Bill Act (the "Act"), the impact of global pandemics on our business, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words, and the use of future dates. Such forward-looking statements are based on the reasonable beliefs of our management as well as assumptions made by and information currently available to our management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or

— FINANCIAL INFORMATION

Part I — FINANCIAL INFORMATION

Condensed Consolidated Financial Statements (unaudited)

Item 1. Condensed Consolidated Financial Statements (unaudited) 5 ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) (unaudited) Assets June 30, 2025 December 31, 2024 Current Assets Cash and cash equivalents $ 217,797 $ 144,861 Restricted cash 36 33 Accounts receivable, net of $ 120,421 and $ 127,824 of adjustments for chargebacks and other allowances at June 30, 2025 and December 31, 2024, respectively 225,654 221,726 Inventories 138,315 136,782 Prepaid expenses and other current assets 15,110 17,975 Investment in equity securities 5,718 6,307 Total Current Assets 602,630 527,684 Non-current Assets Property and equipment, net 59,247 56,863 Deferred tax assets, net of deferred tax liabilities and valuation allowance 92,025 85,106 Intangible assets, net 520,320 541,834 Goodwill 60,533 59,990 Derivatives and other non-current assets 8,246 12,220 Total Assets $ 1,343,001 $ 1,283,697 Liabilities, Mezzanine Equity, and Stockholders' Equity Current Liabilities Current debt, net of deferred financing costs $ 13,216 $ 9,172 Accounts payable 54,569 45,656 Accrued royalties 36,030 22,626 Accrued compensation and related expenses 32,933 37,725 Accrued government rebates 32,866 18,714 Income taxes payable 3,294 6,749 Returned goods reserve 48,683 39,274 Current contingent consideration 483 29 Accrued expenses and other 14,761 13,735 Total Current Liabilities 236,835 193,680 Non-current Liabilities Non-current debt, net of deferred financing costs and current component 301,484 309,108 Non-current convertible notes, net of deferred financing costs 306,862 305,812 Non-current contingent consideration, net of current 18,089 19,825 Accrued licensor payments due 11,428 20,961 Other non-current liabilities 6,696 5,781 Total Liabilities $ 881,394 $ 855,167 Commitments and Contingencies (Note 15) Mezzanine Equity Convertible Preferred Stock, Series A, $ 0.0001

View Full Filing

View this 10-Q filing on SEC EDGAR